Project Grant R01CA316689
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $636K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $388,546 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how chromosome 3q amplification drives non-small cell lung cancer progression through Golgi-dependent secretory pathways and to develop manganese-based targeted therapy for this genetically defined cancer subset. The award funds research into the molecular mechanisms by which two chromosome 3q-encoded...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $582,150 on August 10, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the oncogenic activity and therapeutic targeting of protocadherin 7 (PCDH7) in non-small cell lung cancer. The award funds research into PCDH7's role in lung adenocarcinoma tumorigenesis and the development of therapeutic interventions. The recipient's laboratory has identified PCDH7 as frequently...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $645,186 on August 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop lung cell transplantation therapies for chemotherapy-induced pulmonary fibrosis in cancer patients. The research addresses a significant clinical gap: chemotherapy drugs including bleomycin, methotrexate, and oxaliplatin induce pulmonary fibrosis in cancer patients, and lung transplantation—the only currently...
- The National Cancer Institute awarded The University of Texas Southwestern Medical Center $687,594 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and characterize preclinical models of small cell lung cancer brain metastasis and evaluate therapeutic response. The recipient is conducting research to establish spontaneous brain metastasis models in patient-derived xenografts (PDXs) of small cell lung cancer. The work addresses a critical gap in SCLC research:...
- The National Cancer Institute awarded MD Anderson Cancer Center $669,540 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to elucidate the roles of the CD24 ligand in early lung cancer development, immune evasion, and response to KRAS-targeted therapy. The research investigates CD24 signaling in KRAS-mutant lung adenocarcinomas (KM-LUADs), which account for approximately 30 percent of lung adenocarcinomas in lifetime smokers. Preliminary findings indicate CD24 elevation...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $192,224 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on secreted peptides as biomarkers and effectors of neuroendocrine transformation in lung cancer. The funded work investigates pulmonary neuroendocrine cell (PNEC) biology and the histologic transformation of lung adenocarcinoma to small cell lung cancer. The research employs a genetically engineered...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $639,514 on June 1, 2026, for mechanistic characterization of NVL inhibition by benzothiazepinones as a non-genotoxic chemotherapy strategy under the Cancer Biology Research program (CFDA 93.396). The award funds research to define the catalytic mechanism of NVL, an essential AAA+ ATPase required for large ribosomal subunit...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $402,011 to The University of Texas Southwestern Medical Center on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how the KEAP1-NRF2 redox-sensing pathway regulates CD8 T-cell adaptation to persistent antigen receptor signaling in cancer and chronic infection contexts. The funded research addresses T-cell exhaustion, a dysfunctional...